The news directly pertains to CRISPR Therapeutics as Morgan Stanley maintains an Underweight rating on the company. This suggests that the analyst believes the stock may underperform compared to other stocks in the market. However, the price target has been slightly raised from $42 to $43, indicating a slightly more positive outlook than before. The impact on the stock price in the short term is neutral as the underweight rating is maintained but the price target is increased.